+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

C

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.

Age: 55Years +All GendersPhase Not Applicable
125 locations
S

Actively Recruiting

Researchers are evaluating how well amivantamab combined with lazertinib or with chemotherapy works in treating participants with epidermal growth factor receptor mutated EGFRm non-small cell lung cancer NSCLC, a common type of lung cancer. This Phase 2b study focuses on patients whose NSCLC is locally advanced or metastatic and who have specific EGFR mutations. The study aims to assess antitumor activity and treatment effects over time. Participants are assigned to one of two treatment groups. One group receives subcutaneous amivantamab combined with oral lazertinib in 28-day cycles, and the other group receives subcutaneous amivantamab combined with intravenous platinum-based chemotherapy carboplatin and pemetrexed in 21-day cycles. Treatment continues until disease progression, withdrawal, death, or investigator decision. The study is open-label and non-randomized, consisting of two parallel cohorts. During the study, participants will undergo regular assessments to monitor tumor response and safety. Key measures include progression-free survival tracked for up to 4 years and 6 months, along with evaluations of adverse events, overall survival, response rates, and duration of response. Researchers will also monitor dose changes and specific side effects such as venous thromboembolic events and dermatologic reactions. Participation may last several years depending on individual treatment and disease course.

Age: 18Years +All GendersPhase 2
205 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
R

Actively Recruiting

Researchers are studying adults with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that cannot be surgically removed or has spread to other parts of the body. This trial aims to compare the levels of drug exposure following treatment with tislelizumab given as a subcutaneous injection versus an intravenous infusion as first-line therapy. The study includes approximately 351 participants and is sponsored by BeOne Medicines. Participants are randomly assigned to one of two groups one group receives tislelizumab 300 mg as a subcutaneous injection on Day 1 of each 21-day cycle, followed by chemotherapy chosen individually the other group receives tislelizumab 200 mg as an intravenous infusion on Day 1 of each 21-day cycle, also followed by individualized chemotherapy. Chemotherapy drugs may include cisplatin, leucovorin, 5-fluorouracil, oxaliplatin, or capecitabine. The study is divided into a screening period, a treatment period, and a follow-up period. Throughout the study, participants will be monitored for drug levels, tumor response, survival, and adverse events for up to two years. Assessments include measuring the steady state trough concentration and area under the concentration-time curve of tislelizumab, as well as evaluating tumor response rates and disease control. Safety and antibody responses will also be tracked. Participants will undergo regular visits to collect medical data and ensure adherence to the treatment plan during the study period.

Age: 18Years +All GendersPhase 3
95 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety and immune response of a fifth dose of the Lyme disease vaccine called VLA15 in healthy individuals aged 7 years and older who have already received four doses of this vaccine. This Phase 3 trial compares the effects of the vaccine against a placebo saline to better understand its protection against Lyme disease. The study is randomized, placebo-controlled, and double-blinded, aiming to assess tolerability and immune response. Participants receive one injection, either VLA15 or saline, into the muscle of the upper arm at their first visit. They are randomized in a 51 ratio to either vaccine or placebo. The timing of the fifth dose varies, occurring either one or two years after the fourth dose from a previous study. The trial includes about 1712 participants and uses an independent data monitoring committee to oversee safety. During approximately 12 months of participation, individuals will attend four clinic visits. These visits include health checks, blood draws to measure immune response, and receiving the study injection during the first visit. Researchers will monitor local and systemic reactions within seven days post-injection, adverse events up to one month, and longer-term safety for up to a year. The main outcomes focus on immune responses to different parts of the vaccine and recording any side effects or new medical conditions.

Age: 7Years +All GendersPhase 3
22 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
P

Actively Recruiting

Researchers are studying muscle invasive bladder cancer to see if combining pembrolizumab, a type of immunotherapy, with radiation therapy after chemotherapy can help patients avoid bladder removal surgery. This phase II trial focuses on patients who have responded well to initial chemotherapy and aims to improve three-year bladder intact event-free survival. The study also evaluates survival rates, recurrence, and treatment side effects in participants. Participants receive photon beam radiation therapy once daily from Monday to Friday for up to 20 treatments. Pembrolizumab is given intravenously on the first day of each 21-day cycle, continuing for up to 18 cycles or about 12 months if there is no disease progression or unacceptable side effects. Before treatment, participants undergo a transurethral resection of bladder tumor TURBT and provide tissue samples. Imaging scans such as CT, MRI, or PET, along with cystoscopy and collection of urine and blood samples, are performed throughout the study. During the study, participants are closely monitored with regular assessments including imaging and questionnaires about symptoms. Follow-up visits occur every 26 weeks until two years after treatment and then annually up to five years. Researchers measure outcomes like bladder intact event-free survival, local recurrence, metastasis-free survival, overall survival, and rates of salvage cystectomy. Safety and treatment-related symptoms are tracked carefully, and specimens are collected for future research.

Age: 18Years +All GendersPhase 2
182 locations
E

Actively Recruiting

Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.

Age: 18Years - 50YearsAll GendersPhase 3
456 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of inclisiran, a subcutaneous injection given twice yearly, in preventing major cardiovascular and limb events in patients who have undergone percutaneous coronary or peripheral endovascular revascularization. This phase 4, randomized, double-blind, placebo-controlled study involves about 6,000 participants with symptomatic atherosclerotic cardiovascular disease, including coronary artery disease and peripheral artery disease. The goal is to understand how inclisiran can be used alongside usual care in real-world clinical settings. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection on Day 1, Month 3 Day 90, and every 6 months thereafter. Treatment starts within 14 days after a successful coronary or peripheral endovascular intervention. Both groups will continue their usual care as directed by their physicians. The study is event-driven and will continue until about 2,380 major events have occurred, with a treatment duration of up to approximately 45 months and an average follow-up of about 36 months. Throughout the study, participants will be regularly monitored for major adverse cardiovascular events and limb events, as well as other outcomes such as cardiovascular death, all-cause death, and venous thromboembolic events. Follow-up will last around 4 years. Assessments include clinical evaluations and ongoing observation to measure the impact of inclisiran compared to placebo while ensuring participant safety and adherence to the study protocol.

Age: 18Years +All GendersPhase 4
149 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations

1-10 of 19

1